Analysts Expect Zynerba Pharmaceuticals Inc (ZYNE) to Post -$0.72 Earnings Per Share

Brokerages forecast that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will report earnings of ($0.72) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Zynerba Pharmaceuticals’ earnings. Zynerba Pharmaceuticals reported earnings of ($0.60) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 20%. The company is expected to report its next earnings results on Monday, March 11th.

On average, analysts expect that Zynerba Pharmaceuticals will report full year earnings of ($3.13) per share for the current year, with EPS estimates ranging from ($3.18) to ($3.06). For the next year, analysts expect that the firm will report earnings of ($2.61) per share, with EPS estimates ranging from ($2.68) to ($2.57). Zacks’ EPS calculations are an average based on a survey of analysts that cover Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Thursday, November 8th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.23.

ZYNE has been the subject of several recent analyst reports. Canaccord Genuity set a $18.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 13th. HC Wainwright set a $23.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 13th. ValuEngine cut Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 20th. Cantor Fitzgerald set a $20.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, Zacks Investment Research cut Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $18.93.

ZYNE stock opened at $5.95 on Friday. The company has a market cap of $102.22 million, a P/E ratio of -2.40 and a beta of 4.49. Zynerba Pharmaceuticals has a fifty-two week low of $5.03 and a fifty-two week high of $15.14.

In other news, Director John P. Butler purchased 5,000 shares of the business’s stock in a transaction on Wednesday, August 22nd. The shares were bought at an average price of $6.43 per share, with a total value of $32,150.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $32,150. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 12.67% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its position in Zynerba Pharmaceuticals by 385.6% during the first quarter. JPMorgan Chase & Co. now owns 12,217 shares of the company’s stock worth $106,000 after buying an additional 9,701 shares during the period. Thompson Siegel & Walmsley LLC acquired a new position in Zynerba Pharmaceuticals during the third quarter worth approximately $157,000. Raymond James & Associates acquired a new position in Zynerba Pharmaceuticals during the second quarter worth approximately $164,000. Zeke Capital Advisors LLC acquired a new position in Zynerba Pharmaceuticals during the third quarter worth approximately $193,000. Finally, Engineers Gate Manager LP acquired a new position in Zynerba Pharmaceuticals during the second quarter worth approximately $231,000. 14.08% of the stock is currently owned by institutional investors.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

See Also: What are the Different Types of Leveraged Buyouts?

Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply